'designing' 검색 결과

Analyzes base-editing screens for variant function. Covers library design (Sanson 2020 GRACE, Hanna 2021 BRCA1/2 SNV scanning, Cuella-Martin 2021), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end, wider for ABE8e), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs and analyzes combinatorial CRISPR screens covering paired-Cas9 (Big Papi, Najm 2018), enhanced AsCas12a multiplex (enCas12a, DeWeirdt 2021), in4mer 4-guide-array Cas12a (Esmaeili Anvar N et al 2024 Nat Commun 15:3577) and the Inzolia paralog-pair library, paralog-buffering detection (Dede 2020 Genome Biol; Thompson 2021 Cell Reports 36:109597), genetic-interaction (GI) scoring as observed_double_LFC minus expected_additive_double_LFC, synthetic-lethal and synthetic-rescue interaction interpretation, the half-of-essentiality buffered by paralogs phenomenon, multiplex screen statistical analysis with MAGeCK MLE interaction terms, and the relationship to single-cell combinatorial Perturb-seq. Use when designing a paralog or pathway-pair screen, choosing between paired-Cas9 (Big Papi) and Cas12a multiplex (Inzolia), interpreting genetic interaction scores, identifying synthetic-lethal targets for drug development, or scaling beyond single-gene CRISPR screens.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs and analyzes in vivo CRISPR screens in animal tumor models, organoids, and immune-cell adoptive transfers. Covers bottleneck math (250x cells/sgRNA requires ~25M cells implanted; impossible for most syngeneic models, forcing focused libraries), focused library design (Manguso 2017 Nature 547:413 immune screen; Chen 2015 tumor screens), CRISPR-StAR intrinsic-control screening (Uijttewaal 2025 Nat Biotechnol 43:1848), clonal-dynamics-limited detection, tumor-explant DNA recovery, syngeneic vs xenograft vs PDX considerations, and the relationship to downstream MAGeCK / drugZ analysis. Use when designing in vivo CRISPR screens for tumor / immune / metastasis biology, choosing focused vs genome-wide for animal models, addressing bottleneck-induced clonal collapse, picking the syngeneic / xenograft / PDX model, integrating in vivo with in vitro results, or applying CRISPR-StAR for animal experiments.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Download large datasets from NCBI efficiently using EPost, history server, batching, rate limiting, and retry logic. Use when bulk-fetching tens of thousands of sequences, pulling all results of a large ESearch, designing reproducible pipelines, comparing E-utilities to NCBI Datasets v2 CLI, or implementing checksum-validated downloads. Encodes WebEnv TTL (~8h), EPost 200-ID limit, retmax caps, parallelization design, and integrity verification.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs pooled sgRNA libraries for CRISPR knockout, interference (CRISPRi), activation (CRISPRa), Cas12a multiplex, base-editor, and prime-editor screens. Covers on-target scoring (Rule Set 2, Azimuth, DeepSpCas9, CRISPRon), off-target scoring (CFD, MIT), TSS-relative positioning for CRISPRi/a (Horlbeck, Dolcetto, Calabrese), PAM-variant chemistries, control-guide composition, oligo cloning architecture, and library QC. Use when choosing a genome-wide library (GeCKOv2 vs Avana vs Brunello vs TKOv3 vs Inzolia), designing a focused or paralog-focused custom library, picking CRISPRi vs CRISPRa TSS windows, deciding control-guide proportions, or diagnosing library skew and dropout in a freshly cloned pool.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 (Mathis 2023/2024) for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2 / PE3 / PE3b / PEmax / PEAR variants, MOSAIC in situ saturation mutagenesis (Hsu JY et al 2024 bioRxiv), the PRIME pooled-screen methodology (Erwood/Doman 2023 Nat Biotechnol 41:885; ~3,699 ClinVar variant screens), chromatin context as a primary determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Reconstruct ancestral states at internal phylogenetic nodes for sequences (PAML codeml, IQ-TREE --ancestral, GRASP, FastML), discrete traits (corHMM hidden-rate Markov, ape::ace, phytools::make.simmap stochastic mapping, BayesTraits), and continuous traits (phytools::fastAnc, geiger Brownian/OU, RPANDA). Use when designing constructs for ancestral protein resurrection, tracing trait evolution along a tree, performing stochastic character mapping, testing models of trait evolution (BM vs OU vs EB), inferring ancestral genome content via Dollo or DTL reconciliation, or quantifying ancestral-state uncertainty for downstream comparative analyses.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Identify differentially bound regions across CLIP-seq conditions (knockdown vs control, treatment vs vehicle, disease vs healthy) using DEWSeq (sliding-window DESeq2), Flipper (Skipper-downstream), ASpeak, edgeR, or limma-voom. Use when computing condition-level changes in RBP binding intensity, choosing peak-level vs window-level vs crosslink-level testing, designing replicate experiments, or distinguishing biological binding shifts from technical confounders.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs novel molecules using REINVENT 4 (de novo, scaffold decoration, linker design, R-group, molecular optimization), MolMIM, Diffusion-based generators (DiGress, DiffSMol), and JT-VAE with explicit handling of multi-parameter optimization (MPO), goal-directed scoring functions, transfer/reinforcement/curriculum learning, synthetic accessibility scoring, and chemical space exploration vs exploitation. Use when designing new chemical matter against a target, decorating a scaffold, linking fragments, or optimizing a hit for multiple ADMET / activity properties simultaneously.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs PROTACs, molecular glues, and bivalent degraders with explicit handling of E3 ligase choice (VHL, CRBN, IAP, MDM2, KEAP1), linker design (length, composition, rigidity), ternary complex prediction (PRosettaC, DeepTernary, AlphaFold3 with constraints), cooperativity (alpha), DC50 / Dmax characterization, hook effect, and prediction-experiment reconciliation. Use when designing targeted protein degraders, planning linker SAR, predicting ternary complex stability, or building generative degrader workflows.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Designs covalent inhibitors and warheads targeting cysteine (most common, 98% of covalent drugs), lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Predicts whether a DNA variant alters mRNA splicing using sequence-based deep-learning tools — SpliceAI (10kb context dilated CNN, clinical default), Pangolin (multi-tissue), MMSplice (modular per-region CNN with calibrated ΔPSI), SpliceTransformer/TrASPr (tissue-aware transformers), SpliceVault (empirical 300K-RNA lookup of likely mis-splicing outcomes), CADD-Splice (composite score). Applies the ClinGen SVI 2023 framework for ACMG/AMP variant interpretation (PVS1, PP3, BP4 evidence codes), HGVS splicing nomenclature (c.123+1G>A, c.123-3T>G, r.spl?), extended-window scoring for deep-intronic pseudoexons, tissue-specific predictions, branchpoint variant detection (BPHunter, LaBranchoR), and splice-switching ASO design. Use when interpreting splice impact of clinical variants, prioritizing VUS, identifying deep-intronic pathogenic variants, or designing ASOs.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Assesses RNA-seq data quality specifically for alternative splicing analysis. QC layers include experimental design audit (library prep, read length, depth, replicates), STAR 2-pass cohort-style alignment, junction saturation curves and discovery plateau detection, novel-vs-known junction ratio diagnostics, junction-overhang distribution, splice-site strength scoring (MaxEntScan intrinsic + SpliceAI context-aware), strandedness verification, GENCODE basic vs comprehensive choice, and rRNA contamination screening. Splicing analysis is more demanding than DGE on read length, depth, library prep, alignment strategy, and annotation choice — failures silently bias PSI estimates and inflate novel-junction false positives. Use when evaluating data suitability for splicing analysis, troubleshooting low event detection, or designing sequencing experiments where AS is a primary endpoint.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Use when introducing a feature flag system, choosing between release flags / experiment flags / operational flags / kill switches / permission flags, designing percentage rollouts, building kill-switch + circuit-breaker patterns, structuring evaluation contexts (user IDs, plan tier, region), or building flag-cleanup discipline. Triggers: LaunchDarkly / GrowthBook / Unleash / Flagsmith / OpenFeature, percentage ramp, sticky bucketing, kill switch wired to alerting, "we still have flags from 2 years ago", flag debt, OpenFeature provider, evaluation context, default value on provider failure. NOT for A/B test statistical analysis (separate skill), traffic-split routing at the edge, build-time bundler defines, or environment-based config.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Design error handling strategies for TypeScript and Python applications — exception hierarchies, Result/Either types, retry patterns, error boundaries, and structured error logging. Use when designing error handling architecture, choosing between exceptions and Result types, implementing retry logic, or building error recovery flows. Activate on "error handling", "exception hierarchy", "Result type", "retry pattern", "circuit breaker", "error boundary", "Pokemon exception". NOT for debugging specific runtime errors, logging infrastructure setup, or monitoring/alerting configuration.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Schema design, normalization decisions, indexing strategies, and migration safety for relational databases. Use when designing tables, choosing between normalize vs denormalize, selecting index types, planning zero-downtime migrations, or setting up connection pooling. Activate on "schema design", "normalization", "denormalization", "foreign key", "index strategy", "migration", "connection pooling", "composite key", "surrogate key", "soft delete", "polymorphic association". NOT for PostgreSQL-specific query tuning or EXPLAIN analysis (use postgresql-optimization), NoSQL or document database design, or cloud database provisioning.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

### 1. The Fault/Error/Failure Hierarchy NOT for unrelated tasks outside this domain.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Use when optimizing Docker builds with BuildKit, designing multi-stage Dockerfiles, leveraging cache mounts, building multi-arch images, choosing distroless vs alpine, or signing images with cosign. Triggers: docker build slow, layer cache not hitting, npm install / pip install reruns, multi-stage final image bloat, glibc vs musl issues, RUN --mount=type=cache, BUILDKIT_INLINE_CACHE, registry cache exporters, qemu emulation for arm64, COPY ordering for cache. NOT for Docker daemon admin, Kubernetes-specific image policies, container security scanning workflows, or Buildpacks (different paradigm).

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Use when applying Cloudflare D1 migrations, fighting Supabase migration history vs SQL execution, choosing direct psql over CLI, designing idempotent migrations, debugging schema drift between local and remote, or recovering after a half-applied migration. Triggers: supabase migration repair instructions appearing, table missing after "applied" status, "Tenant or user not found" when running psql, --remote vs --local D1 confusion, NOT NULL on a populated column, foreign key constraint failures, drift between staging and prod schemas. NOT for Mongo/document migrations, ORM-managed migrations specifically (Prisma/Drizzle have their own conventions), or pure data backfills.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Audit whether an enforced-coordination MCP has actually shrunk its ~19 legacy etiquette verbs into the 5 enforced tools — work/act/ask/recall/status — each carrying one denial shape and one transcript event, migrated through a real retirement path (intake-metadata, alias, or doc-history — never a parallel runtime), with zero legacy-verb calls once a body reaches compliance mode C4+. Use when reviewing a broker-collapse migration plan, gating a body's move from advisory (C0-C3) to enforced (C4+) coordination, or verifying IT-018 Broker Collapse compliance. NOT for the inbound trigger→spawn boundary that decides whether an event may spawn an agent at all (use fleet-event-spawn-trust), the capability-token cryptographic mechanism behind a denial (use agentic-zero-trust-security), designing how a swarm of agents invokes and shards work (use swarm-invocation-designer), or auditing an individual PR's mergeability (use agent-pr-authoring).

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Use when designing or fixing a Content Security Policy on a real site, choosing between nonce-based and hash-based CSP, adding strict-dynamic, debugging "Refused to execute inline script" errors, deploying CSP in report-only mode first, configuring report-to / report-uri, or auditing an existing policy for unsafe-inline / unsafe-eval / wildcards. Triggers: "CSP blocks legitimate inline script", strict-dynamic, nonce-{RANDOM}, sha256-{HASH}, object-src none, base-uri none, frame-ancestors, Trusted Types, X-Content-Security-Policy obsolete, report-only vs enforced. NOT for general HTTP security headers (HSTS, COOP/COEP), Trusted Types deep dive, CORS configuration, or building a WAF.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.